Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONC1-0013B in mCRPC
NCT03074032Phase 1Completed
- Start
- Jun 2014
- Primary completion
- Apr 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ONC1-13B in metastatic castration-resistant prostate cancer (mCRPC). Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Jun 2014; status: completed.
02
Drugs
ONC1-13B
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03074032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03074032.